As such, the combined inhibition of STAT3, a protumorigenic signal activated in TLR9-stimulated tumor cells, with CPG-ODNs led to the suppression of subcutaneous or intratibial castrate-resistant prostate tumors in mice [36]. Here, TLR9 is linked to prostate neoplasm.